ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Aroa Biosurgery's annualizedNet Income for the quarter that ended in Mar. 2026 was A$10.08 Mil.
Aroa Biosurgery's average Total Assets over the quarter that ended in Mar. 2026 was A$97.95 Mil. Therefore, Aroa Biosurgery's annualized ROA % for the quarter that ended in Mar. 2026 was 10.29%.
The historical rank and industry rank for Aroa Biosurgery's ROA % or its related term are showing as below:
ASX:ARX'
s ROA % Range Over the Past 10 Years
Min: -20.27 Med: -5.7 Max: 3.97
Current: 3.97
During the past 7 years, Aroa Biosurgery's highest ROA % was 3.97%. The lowest was -20.27%. And the median was -5.70%.
ASX:ARX's ROA % is ranked better than 65.81% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.56
vs ASX:ARX: 3.97
Aroa Biosurgery (ASX:ARX) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Aroa Biosurgery ROA % Related Terms
Aroa Biosurgery ROA % Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Aroa Biosurgery's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's ROA % distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Aroa Biosurgery (ASX:ARX) has a ROA % of 10.29% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Aroa Biosurgery and its competitors. According to the industry distribution chart, Aroa Biosurgery ranks #293 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 34.2%.
Is Aroa Biosurgery's ROA % too high?
Aroa Biosurgery's current ROA % is 10.29%. The Medical Devices & Instruments industry median ROA % is 0.56. Aroa Biosurgery's value of 10.29% is 1737.5% above this industry median. Based on the distribution chart, Aroa Biosurgery ranks #293 out of 857 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Aroa Biosurgery has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #293 out of 857 companies for ROA %. This puts Aroa Biosurgery in the upper half of its industry. The industry median ROA % is 0.56. Aroa Biosurgery's value of 10.29% is 1737.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.56, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aroa Biosurgery's current ROA % of 10.29% is 1737.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Aroa Biosurgery and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aroa Biosurgery's current ROA % is 10.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.80, compared to a current price of A$0.59 — trading 26.3% below its estimated fair value. The current ROA % is 10.29% and 1737.5% above the Medical Devices & Instruments industry median of 0.56. Aroa Biosurgery's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current ROA % is 10.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of A$0.59 is trading 26.3% below its estimated GF Value™ of A$0.80.
GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.
Key valuation signals for ASX:ARX:
ROA %: 10.29%
GF Value™: A$0.80 vs. price of A$0.59 (26.3% below fair value)
Industry Position: 1737.5% above the Medical Devices & Instruments median (#293 of 857)
No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
62GF Score
Get the complete analysis for ASX:ARX
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ARX has been successfully added to your 
